Enocitabine

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 540116

CAS#: 55726-47-1

Description: Enocitabine is a cytarabine derivative, cytosine analog and DNA chain terminator. It also inhibits replication and growth of cytomegalovirus.

Chemical Structure

img
Enocitabine
CAS# 55726-47-1
Instruction

Theoretical Analysis

MedKoo Cat#: 540116
Name: Enocitabine
CAS#: 55726-47-1
Chemical Formula: C31H55N3O6
Exact Mass: 565.41
Molecular Weight: 565.790
Elemental Analysis: C, 65.81; H, 9.80; N, 7.43; O, 16.97

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: BH-AC; BHAC; BH AC; Sunrabin; NSC-239336; NSC239336; NSC 239336; Enocitabine; Arabinoside.

IUPAC/Chemical Name: N-(1-((2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-2-oxo-1,2-dihydropyrimidin-4-yl)docosanamide

InChi Key: SAMRUMKYXPVKPA-VFKOLLTISA-N

InChi Code: InChI=1S/C31H55N3O6/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-27(36)32-26-22-23-34(31(39)33-26)30-29(38)28(37)25(24-35)40-30/h22-23,25,28-30,35,37-38H,2-21,24H2,1H3,(H,32,33,36,39)/t25-,28-,29+,30-/m1/s1

SMILES Code: CCCCCCCCCCCCCCCCCCCCCC(NC(C=CN1[C@H]2[C@H]([C@@H]([C@@H](CO)O2)O)O)=NC1=O)=O

Appearance: Solid powder

Purity: >95% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 565.79 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Ito Y, Wakita A, Takada S, Mihara M, Gotoh M, Ohyashiki K, Ohtake S, Miyawaki S, Ohnishi K, Naoe T. Phase 1 trial of gemtuzumab ozogamicin in combination with enocitabine and daunorubicin for elderly patients with relapsed or refractory acute myeloid leukemia: Japan Adult Leukemia Study Group (JALSG)-GML208 study. Int J Hematol. 2012 Oct;96(4):485-91. doi: 10.1007/s12185-012-1165-z. Epub 2012 Sep 6. PubMed PMID: 22956429.

2: Tatetsu H, Asou N, Nakamura M, Koh Y, Tajiri T, Matsuno F, Horikawa K, Yonemura Y, Mitsuya H. [Allergic reaction against an emulsifier, HCO-60, contained in multamin and enocitabine]. Rinsho Ketsueki. 2003 Jul;44(7):471-3. Japanese. PubMed PMID: 12931567.

3: Terui Y. [Cytidine]. Nihon Rinsho. 2015 Feb;73 Suppl 2:159-61. Japanese. PubMed PMID: 25831743.

4: Chubachi A, Kuriya S, Narigasawa Y, Meguro K, Endo K, Takami H, Sato S, Sasaki H, Shiga T, Maruyama Y, et al. [Response-oriented salvage chemotherapy with mitoxantrone, etoposide and enocitabine for previously treated acute myeloid leukemia. Tohoku Leukemia Study Group]. Gan To Kagaku Ryoho. 1995 Dec;22(14):2101-6. Japanese. PubMed PMID: 8607622.

5: Fujiwara F, Yoshihara T, Ikushima S, Esumi N, Todo S, Morioka Y, Imashuku S, Okano S, Hashida T, Ishii T, et al. [Urotoxicity of enocitabine (BH-AC) and aclarubicin (ACM) in pediatric patients with hematological malignancies]. Rinsho Ketsueki. 1988 Sep;29(9):1388-93. Japanese. PubMed PMID: 3063854.

6: Ninomiya H, Hanada T, Nakazawa M, Aoki Y, Shibuya A, Nagasawa T, Abe T. Immunological erythroblastopenia induced by HCO-60 as a solvent of enocitabine (BH-AC). Nihon Ketsueki Gakkai Zasshi. 1987 Jul;50(4):777-83. PubMed PMID: 3120451.

7: Ota K. [Cytarabine]. Gan To Kagaku Ryoho. 1987 Oct;14(10):2983-7. Japanese. PubMed PMID: 3478003.

8: Ninomiya H, Nakazawa M, Shibuya A, Aoki Y, Nagasawa T, Abe T. Successful treatment of acute megakaryoblastic leukaemia. Scand J Haematol. 1986 Feb;36(2):147-53. PubMed PMID: 3458290.

9: Yamauchi T, Arai H, Taga M, Amaya N, Lee JD, Ueda T. [Adams-Stokes attack due to complete atrioventricular block in a patient with acute promyelocytic leukemia during remission induction therapy using all-trans retinoic acid]. Rinsho Ketsueki. 2005 Mar;46(3):206-10. Japanese. PubMed PMID: 16447716.

10: Shimizu H, Saitoh T, Hatsumi N, Takada S, Handa H, Jimbo T, Sakura T, Miyawaki S, Nojima Y. Prevalence of extramedullary relapses is higher after allogeneic stem cell transplantation than after chemotherapy in adult patients with acute myeloid leukemia. Leuk Res. 2013 Nov;37(11):1477-81. doi: 10.1016/j.leukres.2013.08.017. Epub 2013 Sep 5. PubMed PMID: 24054717.

11: Yoon JH, Cho BS, Kim HJ, Kim JH, Shin SH, Yahng SA, Lee SE, Eom KS, Kim YJ, Lee S, Min CK, Cho SG, Kim DW, Lee JW, Min WS, Park CW. Outcomes of elderly de novo acute myeloid leukemia treated by a risk-adapted approach based on age, comorbidity, and performance status. Am J Hematol. 2013 Dec;88(12):1074-81. doi: 10.1002/ajh.23576. Epub 2013 Sep 12. PubMed PMID: 23983148.

12: Kim HJ, Ahn HK, Jung CW, Moon JH, Park CH, Lee KO, Kim SH, Kim YK, Kim HJ, Sohn SK, Kim SH, Lee WS, Kim KH, Mun YC, Kim H, Park J, Min WS, Kim HJ, Kim DH; L/MDS working party, Korean Society of Hematology. KIT D816 mutation associates with adverse outcomes in core binding factor acute myeloid leukemia, especially in the subgroup with RUNX1/RUNX1T1 rearrangement. Ann Hematol. 2013 Jan;92(2):163-71. doi: 10.1007/s00277-012-1580-5. Epub 2012 Sep 28. PubMed PMID: 23053179.

13: Izumi H, Hirano S, Matsushita Y, Iguchi H, Tone H, Takeuchi T. Experimental combination chemotherapy of pirarubicin with various antitumor drugs against P388 murine leukemia. Cancer Biochem Biophys. 1994 Sep;14(2):137-49. PubMed PMID: 7889494.

14: Huh J, Kim HJ, Jung CW, Kim HJ, Kim SH, Kim YK, Kim HJ, Shin MG, Moon JH, Sohn SK, Kim SH, Lee WS, Won JH, Mun YC, Kim H, Park J, Min WS, Kim DH; AML/MDS working party, Korean Society of Hematology. A genome-wide single-nucleotide polymorphism-array can improve the prognostic stratification of the core binding factor acute myeloid leukemia. Am J Hematol. 2012 Oct;87(10):961-8. doi: 10.1002/ajh.23281. Epub 2012 Aug 7. PubMed PMID: 22886749.

15: Fukushima T, Urasaki Y, Yamaguchi M, Ueda M, Morinaga K, Haba T, Sugiyama T, Nakao S, Origasa H, Umehara H, Ueda T. A randomized comparison of modified intermediate-dose Ara-C versus high-dose ara-c in post-remission therapy for acute myeloid leukemia. Anticancer Res. 2012 Feb;32(2):643-7. PubMed PMID: 22287757.

16: Myoken Y, Sugata T, Katayama Y, Murayama SY. Prompt and definitive diagnosis of acute invasive Aspergillus rhinosinusitis in a patient with acute myeloid leukaemia using in situ hybridization: a case report. Mycoses. 2012 Mar;55(2):e23-6. doi: 10.1111/j.1439-0507.2011.02077.x. Epub 2011 Jul 29. PubMed PMID: 21797938.

17: Niiyama S, Amoh Y, Watarai A, Katsuoka K, Mukai H. Cutaneous myeloid sarcoma presenting as grey pigmented macules. Acta Derm Venereol. 2012 Nov;92(6):629-30. doi: 10.2340/00015555-1312. PubMed PMID: 22278733.

18: Nakamura K, Eizuru Y, Kumura K, Minamishima Y. Antiviral effect of antileukemic drugs N4-behenoyl-1-beta-D-arabinofuranosylcytosine (BH-AC) and 2,2'-anhydro-1-beta-D-arabinofuranosylcytosine (cyclo-C) against human cytomegalovirus. J Med Virol. 1990 Jun;31(2):141-7. PubMed PMID: 1696958.

19: Yokoyama Y, Suzukawa K, Okoshi Y, Nanmoku T, Obara N, Enami T, Hasegawa Y, Chiba S. Nine years interval between first and second bone marrow transplantations and subsequent long-term survival--a case of acute myeloid leukemia with MLL-AF6 fusion gene. Ann Hematol. 2012 Sep;91(9):1491-3. doi: 10.1007/s00277-012-1417-2. Epub 2012 Feb 4. PubMed PMID: 22307741.

20: Kanda Y, Chiba S, Honda H, Hirai H, Yazaki Y. Long-term third chronic phase of chronic myelogenous leukemia maintained by interferon-alpha and methotrexate. Leuk Lymphoma. 1999 Mar;33(1-2):193-7. Review. PubMed PMID: 10194138.